** Shares of some weight-loss drug developers rise premarket, after Novo Nordisk's NOVOb.CO experimental next-generation obesity drug achieves lower weight loss than expected in a late-stage trial
** Novo says its drug, CagriSema, helped overweight patients cut their weight by 22.7%, below the 25% it had expected
** Shares of Viking Therapeutics VKTX.O up 11.5%, Structure Therapeutics GPCR.O up 7.1%, Altimmune ALT.O up 2.2% and Amgen AMGN.O climb 5.5% before the bell
** U.S.-listed shares of Novo fall 22.4%, while rival Eli Lilly LLY.N climbs 10%
** Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market
** Lilly's obesity drug, sold as Zepbound in the U.S., led to an average weight loss of nearly 23% in clinical trials
** Up to last close, AMGN down 9.3%, GPCR down 26.5% and ALT down 27.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。